Potassium-sparing diuretics

From WikiLectures

náhled|150px|chemická struktura spironolaktonu náhled|150px|Kalium-kanrenoát (Aldactone®) 125 mg v ampuli pro i. v. aplikaci náhled|150px|chemická struktura amiloridu náhled|150px|chemická struktura kalium-kanrenoátu Potassium-sparing diuretics act as aldosterone antagonists in the collecting duct and in the lower part of the distal tubule. It can be a direct antagonism – e.g. spironolactone acts as a blocker of the mineralocorticoid receptor. On the other hand, for example, amiloride inhibits the transport of Na+ by ion channels in the luminal membrane, thus reducing sodium resorption. This also reduces the loss of potassium into the urine, as the resorption of Na+ from the collecting ducts creates a negative electrical potential in their lumen, which facilitates the secretion of K+ and H+ into the urine.

Representatives[edit | edit source]

We rank among the main representatives:

Indication[edit | edit source]

Increased mineralocorticoid effect due to primary or secondary aldosteronism. Secondary aldosteronism results from heart failure, liver cirrhosis, nephrotic syndrome, and administration of thiazide and loop diuretics.

Adverse effects and toxicity[edit | edit source]

Links[edit | edit source]

Related articles[edit | edit source]

Source[edit | edit source]

Category:Embedded articles Category: Pathophysiology Category:Cardiology Category: Pharmacology Category:Internal medicine Category: Nephrology